e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 29, 2009
The Medicines Company
 
(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-31191   04-3324394
         
(State or Other Jurisdiction
of Incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
8 Sylvan Way
Parsippany, New Jersey 		  07054
     
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code: (973) 290-6000
 
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On September 29, 2009, John P. Kelley resigned as President and Chief Operating Officer and as director of the Company to pursue other interests, effective October 1, 2009. Mr. Kelley will serve as a Special Advisor to the Company’s Chief Executive Officer until the earlier of December 31, 2009 or until he commences other full-time employment. On October 2, 2009, the Company issued a press release regarding Mr. Kelley’s resignation, attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
     (d) Exhibits
 
  99.1   Press release dated October 2, 2009 entitled “The Medicines Company Announces the Resignation of its Chief Operating Officer”

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  THE MEDICINES COMPANY
 		  
Date: October 5, 2009  By:   /s/ Paul M. Antinori    
    Paul M. Antinori   
    Senior Vice President and General Counsel   

 

 

Exhibit Index
Exhibit No.     Description
   
 
99.1     Press release dated October 2, 2009 entitled “The Medicines Company Announces the Resignation of its Chief Operating Officer”